Transfusion-dependent thalassemia Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 - DelveInsight



The Transfusion-dependent thalassaemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Transfusion-dependent thalassaemia pipeline products will significantly revolutionize the Transfusion-dependent thalassaemia market dynamics. 

DelveInsight’s “Transfusion-dependent thalassaemia Market Insights, Epidemiology, and Market Forecast-2032″ report offer an in-depth understanding of the Transfusion-dependent thalassaemia, historical and forecasted epidemiology as well as the Transfusion-dependent thalassaemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Transfusion-dependent thalassaemia Market Report: 

  • The Transfusion-dependent thalassaemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  

  • Secondary iron overload is the main issue with Transfusion-dependent thalassaemia; if handled, it can cause damage to target organs and even death 

  • Transfusion-dependent thalassaemia prevalence is rare in the United States 

  • The prevalence of symptomatic cases of Transfusion-dependent thalassaemia estimates to be approximately 1 in 100,000 individuals in the general population 

  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others 

  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others 

  • Transfusion dependence happens when a patient needs an average of more than 2 units of blood transfused every 28 days for at least three months

Request a sample for the Transfusion-dependent thalassaemia Market Report 

Transfusion-dependent thalassaemia Overview

According to the severity of the phenotype, which is brought on by a wide range of mutations in a homozygous or compound heterozygous state, -thalassemias can be categorised clinically as transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT).

Reduced synthesis of the -globin chain, which causes a /-chain imbalance, the precipitation of -globin-heme complexes, and poor erythropoiesis are the hallmarks of -thalassemias. The disease's hallmarks—ineffective erythropoiesis, persistent hemolytic anaemia, and compensatory hematopoietic expansion—are connected to how severe the chain unbalance is. Numerous clinical variants of beta-thalassemia, such as haemoglobin E/beta-thalassemia, which results from beta-thalassemia coinheritance with haemoglobin E, have been reported. 

Transfusion-dependent thalassaemia Symptoms  

The Transfusion-dependent thalassaemia symptoms include -

  • Body Fatigue

  • Weakness

  • Shortness of breathing

  • Dizziness

  • Headaches

  • Nausea and vomiting

Discover more about therapies set to grab major Transfusion-dependent thalassaemia market share @ Transfusion-dependent thalassaemia market forecast 

Transfusion-dependent thalassaemia Epidemiology Segmentation:

The Transfusion-dependent thalassaemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Transfusion-dependent thalassaemia

  • Prevalent Cases of Transfusion-dependent thalassaemia by severity

  • Gender-specific Prevalence of Transfusion-dependent thalassaemia

  • Diagnosed Cases of Episodic and Chronic Transfusion-dependent thalassaemia 

Transfusion-dependent thalassaemia Market  

The dynamics of the Transfusion-dependent thalassaemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Mitapivat, Deferasirox, and others during the forecasted period 2019-2032.

Download the report to understand which factors are driving Transfusion-dependent thalassaemia epidemiology trends @ Transfusion-dependent thalassaemia Epidemiological Insights

Transfusion-dependent thalassaemia Therapies

  • PTG-300

  • BIVV003

  • Mitapivat 

  • Deferasirox

  • Luspatercept

  • sofosbuvir/velpatasvir

  • Deferasirox dispersable tablet

Transfusion-dependent thalassaemia Key Companies 

  • Celgene

  • bluebird bio

  • Sangamo Therapeutics 

  • Protagonist Therapeutics

  • Novartis Pharmaceuticals 

  • Vertex Pharmaceuticals 

Scope of the Transfusion-dependent thalassaemia Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others

  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others

  • Therapeutic Assessment: Transfusion-dependent thalassaemia current marketed and Transfusion-dependent thalassaemia emerging therapies

  • Migraine Market Dynamics:  Transfusion-dependent thalassaemia market drivers and barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Transfusion-dependent thalassaemia  Market Access and Reimbursement 

To know more about Transfusion-dependent thalassaemia treatment, visit @ Transfusion-dependent thalassaemia Medications 

Related Reports:  

 

Diagnostic Imaging Equipment Market

 

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

 

Invasive Candidiasis Market

 

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.

 

Sialidosis Market 

 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Filgrastim Biosimilar Insight

 

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Pain Management Devices Market

 

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market


To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Comments

Post a Comment

Popular posts from this blog

The Great PD-1 Inhibitor Battle: OPDIVO vs. KEYTRUDA in Japan

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo
Read more

A detailed analysis of Vascular Stents Market Trends, Growth Opportunities, Challenges, and Epidemiology Forecast

Image
A vascular surgeon places a stent, which is a hollow mesh tube that supports the blood vessel's walls permanently and prevents it from closing up again (restenosis). Some stents are drug-eluting, which means they release medicine over time to help prevent another blockage. The  Vascular Stents market is being driven by a growing geriatric population as well as an increase in the number of surgical operations. The  Vascular Stents Market report from DelveInsight provides an in-depth analysis of  Vascular Stents, as well as historical and forecasted market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some Key Highlights from the  Vascular Stents Market Report The artery is kept open by a stent, which is a small metal mesh tube. The two methods for opening clogged peripheral arteries are angioplasty and stent implantation. Vascular Stents market is segmented on the basis of Product type, By Applications and End-user. Some of the
Read more
Image
Obstructive Sleep Apnea Market Trends and Therapeutic Advancements !! Obstructive Sleep Apnea (OSA) is a common chronic sleep disorder, which is characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to a complete or partial obstruction of the airway, results of which are apneas, hypopneas, or sometimes both. Obstructive sleep apnea is a chronic and permanent condition, through proper therapy and medications the condition can be cured. Almost every system in the body is affected by Obstructive Sleep Apnea, resulting in an increased incidence of hypertension, stroke, altered immune system, and cardiovascular disease.  Obstructive Sleep Apnea is caused when the throat muscles relax during sleep, which causes the tissue in the back of the throat to collapse and block the upper airway. Daytime sleepiness is one of the most common symptoms of Obstructive Sleep Apnea. People affected with Obstructive Apnea also complain of memory problems, headach
Read more